Skip to main content
CMEducation Resources ScrollCall
  • menu
  • menu
  • person
  • Search
  • Specialty
  • Cardiology chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • Diabetes chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • Specialty Program
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Cytokine Immunotherapy chevron_right
  • Hypothyroidism chevron_right
  • Specialty Program
  • Parkinson's Diseasechevron_right
  • Specialty
  • Cancer chevron_right

  • Specialty Program
  • Cytokine Immunotherapy chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Pain Management chevron_right
  • Specialty
  • Primary Care chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Parkinson's Diseasechevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • Specialty
  • Dermatology chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Specialty
  • Biologicschevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Biosimilars for RA chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • MAC Lung Disease chevron_right

  • Specialty Program
  • MAC Lung Disease chevron_right
    • close
    CMEducation Resources iQ&A
    • person
    • Home
    • Specialtieschevron_right
      • chevron_leftTopics
      • Cardiology
      • Diabetes
      • Endocrinology
      • Neurology
      • Cancer
      • Primary Care
      • Dermatology
      • Biologics
      • MAC Lung Disease
    • Submit A Question
    close

    Mike Ruma, MD, MPH, FACOG

    Mike Ruma, MD, MPH, FACOG

    Maternal–Fetal Medicine Specialist
    Perinatal Associates of New Mexico
    Albuquerque, NM


    Related Videos

    What is the rationale for deploying SNP-based NIPT in larger swaths of the population, especially in lower risk populations? Do recent ACMG guidelines suggest a value in low risk patients? Video

    What is the rationale for deploying SNP-based NIPT in larger swaths of the population, especially in lower risk populations? Do recent ACMG guidelines suggest a value in low risk patients?

    What is the rationale for deploying SNP-based NIPT in larger swaths of the population, especially in lower risk populations? Do recent guidelines — from the ACMG — suggest there is value using cell-free DNA tests in low risk patients?

    Why is there is a discrepancy between cell-free DNA testing and ultrasound regarding the sex of the baby? Video

    Why is there is a discrepancy between cell-free DNA testing and ultrasound regarding the sex of the baby?

    Why is there is a discrepancy between cell-free DNA testing and ultrasound regarding the sex of the baby?

    Since the technology for cell- free DNA/SNP-based testing can be complex, how do you work with the companies and what kind of technical support is required to optimize NIPT in this context? Video

    Since the technology for cell- free DNA/SNP-based testing can be complex, how do you work with the companies and what kind of technical support is required to optimize NIPT in this context?

    Since the technology for cell- free DNA/SNP-based testing can be complex, how do you work with the companies and what kind of technical support is required to optimize NIPT in this context?

    How do you work with genetic counselors to optimize the value of cell-free DA test results for NIPT in your patients? Video

    How do you work with genetic counselors to optimize the value of cell-free DA test results for NIPT in your patients?

    How do you work with genetic counselors to optimize the value of cell-free DA test results for NIPT in your patients?

    What is the unique value of cell- free DNA, SNP-based testing in the setting of vanishing twins? Why and how is the test employed? What is the limitation of the counting method in this case? Video

    What is the unique value of cell- free DNA, SNP-based testing in the setting of vanishing twins? Why and how is the test employed? What is the limitation of the counting method in this case?

    What is the unique value of cell- free DNA, SNP-based testing in the setting of vanishing twins? Why and how is the test employed? What is the limitation of the counting method in this case?

    What are some of the practical, real world aspects of using SNP-based, cell-free DNA fractions for NIPT? Can you take us through this at the patient care interface? Video

    What are some of the practical, real world aspects of using SNP-based, cell-free DNA fractions for NIPT? Can you take us through this at the patient care interface?

    What are some of the practical, real world aspects of using SNP-based, cell-free DNA fractions for NIPT? Can you take us through this at the patient care interface?

    Would you describe some clinical scenarios that illustrate types of patients for whom you would utilize NIPT, specifically the SNP-based technology, in your clinical practice? Video

    Would you describe some clinical scenarios that illustrate types of patients for whom you would utilize NIPT, specifically the SNP-based technology, in your clinical practice?

    Would you describe some clinical scenarios that illustrate types of patients for whom you would utilize NIPT, specifically the SNP-based technology, in your clinical practice?

    What are some of the causes of false positive results and how does the SNP method aid the clinician to rule out maternal sex chromosome mosaicism/abnormalities? Video

    What are some of the causes of false positive results and how does the SNP method aid the clinician to rule out maternal sex chromosome mosaicism/abnormalities?

    What are some of the causes of false positive results and how does the SNP method aid the clinician to rule out maternal sex chromosome mosaicism/abnormalities?

    What are the benefits of screening for sex chromosome aneuploidies (SCAs)? Video

    What are the benefits of screening for sex chromosome aneuploidies (SCAs)?

    What are the benefits of screening for sex chromosome aneuploidies (SCAs)?

    Disclaimer:
    Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
    Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
    Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
    Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

    Clinical Webcasts®

    Powered by BroadcastMedBROADCASTMED